RCS - Faron Pharma. Oy - Bexmarilimab KOL Event

Faron Pharmaceuticals OyAnnouncement

19/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230419:nRSS6676Wa&default-theme=true

RNS Number : 6676W  Faron Pharmaceuticals Oy  19 April 2023

Faron Pharmaceuticals Oy

 

("Faron or the Company")

 

Bexmarilimab for Hematological Malignancies KOL Event

 

Press Release, April 19, 2023

 

TURKU, FINLAND / BOSTON, MA -  Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON),  a clinical-stage biopharmaceutical company focused on
tackling cancers via novel immunotherapies, today announces plans to host a
virtual KOL event via webcast on Tuesday, April 25 at 11.00 EST/16.00
BST/18.00 EEST with Dr. Naval Daver, MD, Associate Professor of Leukemia at
The University of Texas MD Anderson Cancer Center; Dr. Mika Kontro, MD, PhD,
Associate Professor at the University of Helsinki and Faron management.

 

As part of the event, Dr. Daver will discuss the unmet medical need in acute
myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Dr. Kontro will
provide an update on the most recent Phase I/II BEXMAB data in AML and MDS
patients.

 

The agenda is as follows:

·    Opening remarks and introductions - Dr. Markku Jalkanen, PhD, CEO

·    Unmet medical need in r/r AML and MDS - Dr. Naval Daver, MD,
Scientific Advisor for Faron

·    BEXMAB clinical data in combination with standard of care - Dr. Mika
Kontro, MD, PhD

·    Next steps planned for the study - Dr. Marie-Louise Fjällskog, MD,
PhD, CMO

·    Q&A session

·    Closing remarks

 

Faron reported this week updated additional positive data from its ongoing
Phase I/II BEXMAB study, investigating bexmarilimab, the Company's wholly
owned immunotherapy asset, in combination with standard of care (SoC) in
relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes
(MDS). The latest update included two objective responses (ORR) and two stable
disease (SD) patients observed, with one having > 50% reduction of blast
cells, in the second doublet cohort. Of three patients with ORR in the first
doublet cohort, two remain on the study after 10 and 9 months, respectively,
and the third has undergone a potentially curative transplantation.

 

During the event, Dr. Marie-Louise Fjällskog, Faron's Chief Medical Officer,
will discuss next steps planned for the BEXMAB program. There will be an
opportunity to ask questions during the webcast.

 

"I am delighted to be hosting this KOL Day with Dr. Daver and Dr. Kontro,"
said Dr. Markku Jalkanen, Faron's CEO. "They will provide important insights
into the immunotherapy approaches currently available to patients with
hematological malignancies and the work Faron is doing to potentially bring
the promise of immunotherapy to a broader patient group."

 

To register for the webcast:
https://faron.videosync.fi/kol-call-04-2023/register
(https://faron.videosync.fi/kol-call-04-2023/register) or contact the IR team
for more information at investor.relations@faron.com
(mailto:investor.relations@faron.com) .

For more information please contact:

 

Media Contact

Faron Pharmaceuticals

Jennifer C. Smith-Parker

Head of Communications

Jennifer.Smith-Parker@faron.com (mailto:Jennifer.Smith-Parker@faron.com)

 

Investor Contact

Faron Pharmaceuticals

Julia Balanova

VP, Investor Relations

julia.balanova@faron.com (mailto:julia.balanova@faron.com)

investor.relations@faron.com (mailto:investor.relations@faron.com)

Phone: +1 (917) 306-6096

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

Consilium Strategic Communications

David Daley, Lindsey Neville

faron@consilium-comms.com (mailto:faron@consilium-comms.com)

Phone: +44 (0)20 3709 5700

 

 

About Bexmarilimab

Bexmarilimab is Faron's wholly owned, investigational immunotherapy with the
potential to provide immune stimulation for treatment-resistant cancers
through targeting myeloid cell function. A novel anti-CLEVER-1 humanized
antibody, bexmarilimab targets CLEVER-1 positive (Common Lymphatic Endothelial
and Vascular Endothelial Receptor 1) tumor-associated macrophages (TAMs) in
the tumor microenvironment, converting highly immunosuppressive M2 macrophages
to immune-stimulating M1 macrophages. As an immuno-oncology therapy,
bexmarilimab has therapeutic potential in combination with other standard
treatments including immune checkpoint molecules in both solid tumors and
hematologic malignancies.

 

About BEXMAB

The BEXMAB study is a first-in-human, open-label Phase I/II clinical trial
investigating bexmarilimab in combination with standard of care (SoC) in the
aggressive hematological malignancies of acute myeloid leukemia (AML) and
myelodysplatic syndrome (MDS). The primary objective is to determine the
safety and tolerability of bexmarilimab in combination with SoC (azacytidine)
treatment and to identify the recommended Phase II dose. Directly targeting
CLEVER-1 could limit the replication capacity of cancer cells, increase
antigen presentation, ignite an immune response, and allow current treatments
to be more effective. CLEVER-1 is highly expressed in both AML and MDS and
associated with therapy resistance, limited T cell activation and poor
outcomes.

 

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), together with its
subsidiaries, is a clinical stage biopharmaceutical group focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer. Bexmarilimab, a novel anti-CLEVER-1 humanized antibody, is its
investigational immunotherapy with the potential to remove immunosuppression
of cancers through targeting myeloid cell function. Bexmarilimab is being
investigated in Phase I/II clinical trials as a potential therapy for patients
with hematological and solid cancers in combination with other standard
treatments including immune checkpoint molecules. Faron is headquartered in
Turku, Finland. Further information is available at www.faron.com
(http://www.faron.com/) .

 

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be,
forward-looking statements. Forward looking statements are identified by their
use of terms and phrases such as ''believe'', ''could'', "should", "expect",
"hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'',
''potentially'', ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions. These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

 

A number of factors could cause actual results to differ materially from the
results and expectations discussed in the forward-looking statements, many of
which are beyond the control of the Company. In addition,  other factors
which could cause actual results to differ materially include the ability of
the Company to successfully license its programs within the anticipated
timeframe or at all, risks associated with vulnerability to general economic
and business conditions, competition, environmental and other regulatory
changes, actions by governmental authorities, the availability of capital
markets or other sources of funding, reliance on key personnel, uninsured and
underinsured losses and other factors.  Although any forward-looking
statements contained in this announcement are based upon what the Directors
believe to be reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward-looking statements.
Accordingly, readers are cautioned not to place undue reliance on
forward-looking statements. Subject to any continuing obligations under
applicable law or any relevant AIM Rule requirements, in providing this
information the Company does not undertake any obligation to publicly update
or revise any of the forward-looking statements or to advise of any change in
events, conditions or circumstances on which any such statement is based.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUWCCUPWPUR